ENZAMET and TheraP at top US Conference


The ANZUP-led ENZAMET and TheraP trials were two of only four prostate cancer trials selected for an oral abstract session at the recent American Society of Clinical Oncology annual conference (ASCO22) in Chicago in early June. CTC collaborated on both trials and was heavily involved in the design, coordination, and analysis of results.

ENZAMET Study Co-Chair Prof Ian Davis reported that in participants with metastatic hormone sensitive prostate cancer, the survival benefit of enzalutamide (compared to control) previously reported at 36 months follow-up was maintained at 60 months follow-up. 

TheraP Study Chair Prof Michael Hofman reported that participants with metastatic castrate-resistant prorate cancer treated with LuPSMA had similar overall survival to those treated with cabazitaxel. However, as previously reported, LuPSMa showed lower adverse events, higher response rates, and improved patient-reported outcomes when compared to cabazitaxel.




Media TheraP


Other CTC success at ASCO

An impressive number of posters were either presented by CTC authors or had contributions from the CTC, including the following;